Tests BMS-986453 cell therapy in adults with relapsed or hard-to-treat multiple myeloma
Tests BMS-986453, a modified immune cell treatment, in adults with returning or resistant myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Key facts
- Where
- Madrid, Pamplona, and Salamanca, SpainSee the 3 sites
- Phase
- Phase 1
Where in Spain
- Clinica Universidad de NavarraMadrid, SpainTaking people
- Clínica Universidad de navarraPamplona, SpainTaking people
- Hospital Universitario De SalamancaSalamanca, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Trial code
- NCT06153251EU 2023-506003-26-00
- Record updated
- 18 March 2026
- Original description
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).Read full original descriptionShow less
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Inclusion: Participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease; Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry; Participants in Part A and Part B Cohort 1 and in Part B Cohort 2 must have relapsed/refractory multiple myeloma and received previous antimyeloma therapy, including a proteasome inhibitor and an immunomodulatory agent; Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Participants must have adequate organ function.
Exclusion: Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma; Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis; Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis; Other protocol-defined inclusion/exclusion criteria apply.